This October, Regis Custom Pharma will host two seminars on “Solid Form Selection in the Pharmaceutical Industry: Salt Selection and Polymorphism.” Guest speaker Gregory A. Stephenson, Ph.D. will deliver the technical talks, which are open to the public, in San Diego (10/15) and San Mateo (10/17). Registration is required as […]

Regis Technologies, Inc. is excited to announce a new capability of Solid State Chemistry. The Solid State Chemistry service will provide salt, cocrystal, and polymorph screening and selection activities to provide suitable crystallization processes during all development phases for Regis’ Custom Pharma clients. Solid State Chemistry Director Dr. Ronald L. Mueller has […]

Regis Technologies, a Chicago-based contract development and manufacturing organization focused on small molecule active pharmaceutical ingredients (API), is expanding its operations. To better serve our Custom Pharma clients, we are adding a third shift. This will allow us to run our manufacturing 24 hours a day, five days a week. […]

Regis Technologies is proud to announce the addition of Ronald L. Mueller, Ph.D. to spearhead our newest offering of Solid State Chemistry (SSC). Dr. Mueller has more than 25 years in the pharmaceutical industry and over 20 years of preformulation and solid state chemistry experience. After earning his B.Sc. in […]

Regis Technologies, Inc. reports the successful outcome of its routine U.S. Food & Drug Administration (FDA) inspection which found no objectionable findings. This marks the fourth consecutive, impeccable inspection for Regis and demonstrates its commitment to a standard of excellence in quality and compliance in the pharmaceutical industry. The inspection […]

Congratulations to Michael Kruk for receiving the Analyst of the Year Award for 2018. Michael is an alumnus of Northeastern Illinois University with a Bachelor of Science in Chemistry. He has industry experience via an internship program at Abbvie & Abbott Labs. As an interning chemist there, he received the […]

Each year, Regis’ President & CEO recognizes one employee for outstanding performance. Amongst many deserving nominees, Louis Glunz was honored to present Iram Ruiz with the 2018 President’s Award at our company holiday party on December 8th. Iram joined Regis in late 2013 as a Production Technician. Utilizing excellent problem-solving […]

Regis is happy to announce a new addition to its Process Chemistry department, Eric Buck, Ph.D. Eric joined our team in October 2018 as a Process Development Chemist III. His main responsibility is to safely develop and scale up APIs for commercial manufacturing. Eric graduated from the University of Minnesota […]

This fall, Regis Custom Pharma will host a series of breakfast seminars on “Speeding Drug Development through State-of-the-Art Impurity Control Strategies.” Guest speaker Steven Baertschi, Ph.D. will deliver the technical talks, which are open to the public, in Morton Grove (10/17), South San Francisco (10/31), and San Diego (11/1). Registration […]

Over the past three years, Regis employees have collectively lost hundreds of pounds by participating in our Biggest Loser contests. This summer, we finished our fifth season. Four teams competed, and the winning team lost 5% of its initial body weight. The contest was started from an employee suggestion and […]

In compliance with GDPR standards, Regis has updated its Privacy Policy. Our site now uses cookies, and thus the following has been added to our policy: Cookies A cookie is a small file placed on your computer or device when you visit a website.  We use cookies for various functions, including […]

Congratulations to Nathaniel Kuffel for his promotion to Quality Control Chem II. Nathan holds a Bachelor’s degree in analytical chemistry and Master’s of Science from DePaul University. He earned his Master’s in 2015 while simultaneously gaining industry experience as an intern and research assistant at Perkin Elmer. Shortly after graduating […]

Louis J. Glunz III, Ph.D., was born on June 23, 1930. He founded Regis in 1956 and remains our Chairman today. Regis is a family-owned and operated business, a Glunz tradition since 1888. Dr. Glunz and his father would experiment together in a laboratory on the building’s third floor that […]

Regis Technologies is announcing their entry into the oncology market with the start up of the new Potent Compound Suite (PCS). The PCS allows Regis, a Chicago-based contract manufacturing organization (CMO), to target small molecule oncologicals and linker payload projects for antibody drug conjugates. Regis is a CMO operating a […]